Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, 9713GZ, The Netherlands.
Laboratory of Microbiology, Wageningen University & Research, P.O. Box 8033, Wageningen, 6700 EH, The Netherlands.
Mol Nutr Food Res. 2020 Jun;64(12):e2000251. doi: 10.1002/mnfr.202000251. Epub 2020 May 13.
The prevalence of metabolic-syndrome-related disease has strongly increased. Nutritional intervention strategies appear attractive, particularly with novel prebiotics. Isomalto/malto-polysaccharides (IMMPs) represent promising novel prebiotics that promote proliferation of beneficial bacteria in vitro. The present study investigates for the first time the in vivo effects of IMMP in mice.
C57BL/6 wild-type mice received control or IMMP-containing (10%, w/w) diets for 3 weeks. IMMP leads to significantly more fecal bulk (+26%, p < 0.05), higher plasma non-esterified fatty acids (colorimetric assay, +10%, p < 0.05), and lower fecal dihydrocholesterol excretion (mass spectrometry, -50%, p < 0.05). Plasma and hepatic lipid levels (colorimetric assays following lipid extraction) are not influenced by dietary IMMP, as are other parameters of sterol metabolism, including bile acids (gas chromatography/mass spectrometry). IMMP is mainly fermented in the cecum and large intestine (high-performance anion exchange chromatography). Next-generation sequencing demonstrates higher relative abundance of Bacteroides and butyrate producers (Lachnospiraceae, Roseburia Odoribacter) in the IMMP group.
The combined results demonstrate that IMMP administration to mice increases fecal bulk and induces potentially beneficial changes in the intestinal microbiota. Further studies are required in disease models to substantiate potential health benefits.
代谢综合征相关疾病的患病率大幅上升。营养干预策略似乎很有吸引力，特别是新型的益生元。异麦芽低聚糖/麦芽低聚糖（IMMP）是一种很有前途的新型益生元，能在体外促进有益菌的增殖。本研究首次在小鼠体内研究了 IMMP 的作用。
C57BL/6 野生型小鼠接受对照或含 IMMP（10%，w/w）的饮食 3 周。IMMP 导致粪便量显著增加（+26%，p<0.05），血浆非酯化脂肪酸增加（比色法，+10%，p<0.05），粪便中二氢胆固醇排泄减少（质谱法，-50%，p<0.05）。饮食 IMMP 不影响血浆和肝脂质水平（脂质提取后的比色法），也不影响其他固醇代谢参数，包括胆汁酸（气相色谱/质谱法）。IMMP 主要在盲肠和大肠中发酵（高效阴离子交换色谱法）。下一代测序表明，IMMP 组中拟杆菌和丁酸产生菌（Lachnospiraceae、Roseburia Odoribacter）的相对丰度更高。
综合结果表明，IMMP 给药可增加粪便量，并诱导肠道微生物群的潜在有益变化。需要在疾病模型中进行进一步的研究，以证实其潜在的健康益处。
